Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Brief

Foot and Ankle Surgery Ridgewood, NJ Medical Doctor

NPI 1841206653 CMS profile 37467

85 S Maple Ave, Ridgewood, NJ 07450

Open in the dashboard

General payments

$253,186

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Brief of Ridgewood, NJ is reported in the CMS Open Payments database as having received $253,186 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,130 24
2024 General $11,692 23
2023 General $28,740 23
2022 General $90,019 15
2021 General $26,586 23
2020 General $23,432 12
2019 General $46,588 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Brief
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Andrew Brief were reported at $26,130. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Andrew Brief Foot and Ankle Surgery median Middle half National median
2019 $46,588 $1,327 $279–$5,421 $163
2020 $23,432 $795 $121–$3,473 $114
2021 $26,586 $1,289 $201–$4,963 $132
2022 $90,019 $1,539 $270–$6,067 $149
2023 $28,740 $1,117 $257–$5,264 $160
2024 $11,692 $1,064 $235–$4,944 $164
2025 $26,130 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medartis Inc. $96,291 15 payments
  2. Extremity Medical $76,695 29 payments
  3. Nextremity Solutions Inc. $67,491 10 payments
  4. SeaPearl Inc $3,206 17 payments
  5. Synthes USA Products LLC $2,883 4 payments
  6. Stryker Corporation $2,724 17 payments
  7. Arthrex, Inc. $1,144 11 payments
  8. Bioventus LLC $924 7 payments
  9. DePuy Synthes Sales Inc. $319 10 payments
  10. Wright Medical Technology, Inc. $312 4 payments
  11. Other $1,196 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $236,182 51 payments
  2. Consulting Fee $8,490 8 payments
  3. Food and Beverage $5,129 76 payments
  4. Travel and Lodging $2,492 7 payments
  5. Education $799 1 payment
  6. Gift $94 1 payment
Products named General payments · program years 2019–2025
  1. APTUS Ortho $94,315 10 payments
  2. Omni Orthopedics $68,440 26 payments
  3. Omni Orthopedics $19,952 7 payments
  4. LCP $2,847 2 payments
  5. NA $2,847 2 payments
  6. APTUS Ortho $1,804 4 payments
  7. Exogen $798 4 payments
  8. GAMMA $322 3 payments
  9. Magellan $284 2 payments
  10. MONOVISC $212 9 payments
  11. Other $4,607 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

21

Median for Orthopedic Surgery: 203

Drug cost

$180

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 21 $180

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$154,829

Of which drugs: $5,089

Medicare patients

548

Average age 73

Services billed

2,307

370 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 70%
Ischemic heart disease 30%
Osteoporosis 27%
Diabetes 21%
Depression 18%
Cancer 16%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 111 413 $312

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record